Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1996 1
2007 2
2008 1
2009 2
2013 1
2016 2
2018 3
2019 1
2020 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Hepatitis C Virus: Efficacy of New DAAs Regimens.
Mohamed AA, El-Toukhy NER, Said EM, Gabal HMR, AbdelAziz H, Doss W, El-Hanafi H, El Deeb HH, Mahmoud S, Elkadeem M, Shalby HS, Abd-Elsalam S. Mohamed AA, et al. Among authors: said em. Infect Disord Drug Targets. 2020;20(2):143-149. doi: 10.2174/1871526519666190121114003. Infect Disord Drug Targets. 2020. PMID: 30663575 Review.
Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
Said EM, Abdulaziz BA, Kassas ME, El Attar IH, Emadeldeen M, Abd-Elsalam SM. Said EM, et al. Arch Virol. 2024 Feb 13;169(3):45. doi: 10.1007/s00705-024-05990-z. Arch Virol. 2024. PMID: 38349452 No abstract available.
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. Said EM, et al. Arch Virol. 2020 Jul;165(7):1633-1639. doi: 10.1007/s00705-020-04639-x. Epub 2020 Apr 30. Arch Virol. 2020. PMID: 32356185 Retracted. Clinical Trial.
Three-dimensional echocardiography of the thoracic aorta.
Kasprzak JD, Salustri A, Nosir Y, Taams M, el-Said EM, Roelandt JR. Kasprzak JD, et al. Among authors: el said em. Eur Heart J. 1996 Oct;17(10):1584-92. doi: 10.1093/oxfordjournals.eurheartj.a014725. Eur Heart J. 1996. PMID: 8909918
19 results